Skip to content

GHRP-6 Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

GHRP-6's side effect profile is more pronounced than newer, more selective GHRPs like ipamorelin, though most effects are dose-dependent and transient.

Common:

  • Intense hunger and appetite stimulation (onset within 15 to 20 minutes of injection, lasting 30 to 60 minutes). This is the most frequently reported effect and is inherent to GHRP-6's mechanism
  • Mild water retention and peripheral edema, particularly during the first 2 to 4 weeks
  • Transient flushing, warmth, or dizziness immediately post-injection
  • Injection site reactions (redness, minor swelling)

Less Common:

  • Tingling or numbness in the extremities (hands and feet), related to GH-mediated fluid shifts
  • Head rush or lightheadedness shortly after administration
  • Drowsiness, particularly with evening doses

Dose-Dependent (above saturation dose):

  • Elevated cortisol via ACTH stimulation. Chronic elevation can impair fat loss, disrupt sleep, and suppress immune function
  • Elevated prolactin. In sensitive individuals, sustained elevation may cause gynecomastia or reproductive effects
  • These hormonal effects are generally not observed at doses of 100 mcg or below

Theoretical/Long-Term:

  • Potential effects on glucose metabolism and insulin sensitivity with prolonged use
  • As with all GH-elevating compounds, theoretical concern regarding promotion of growth in undiagnosed malignancies

Water retention and tingling typically diminish within the first few weeks as the body adapts. Starting at a lower dose and titrating upward can minimize initial discomfort.

Frequently Asked Questions

The most common side effect is intense hunger shortly after injection. Other effects include mild water retention, transient flushing or dizziness, and tingling in the extremities. At doses above the saturation threshold, GHRP-6 can elevate cortisol and prolactin levels. These effects are generally dose-dependent and transient.

Ipamorelin is more selective, releasing GH without meaningfully affecting cortisol, prolactin, or appetite at standard doses. GHRP-6 produces a comparable GH pulse but with significant appetite stimulation and modest cortisol and prolactin elevation. Ipamorelin is generally preferred for cleaner side effect profiles, while GHRP-6 may suit those seeking appetite stimulation.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
  2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
  3. Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
  4. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
  5. Leal-Cerro A, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.
  6. Pena-Bello L, et al. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus. Metabolism. 2010;59(11):1536-1542.
  7. Bellone J, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995;133(4):425-430.
  8. Sosa-Hernandez JL, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024;15:1402138.
  9. Berlanga-Acosta J, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-250.
  10. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
  11. World Anti-Doping Agency. The Prohibited List.
  12. Fernandez-Perez L, et al. Pharmacokinetic study of growth hormone-releasing peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”